STAA
Staar Surgical
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About STAA
Staar Surgical Company
A developer of implantable lenses for the eye and companion delivery systems
Healthcare Equipment and Supplies
Invalid Date
10/26/1990
NASDAQ Stock Exchange
1157
12-31
Common stock
25510 Commercentre Drive, Lake Forest, California 92630
--
Staar Surgical Company designs, develops, manufactures and sells implantable lenses. The company is the world's leading manufacturer of lenses used in corrective or "refractive" surgery, and its lenses are also used to treat cataract surgery. All of the company's lenses are foldable, allowing surgeons to insert them through a small incision during minimally invasive surgery. Refractive surgery corrects visual impairment, the traditional treatment of visual impairment such as glasses or contact lenses. The company refers to the lenses used in refractive surgery as "implantable intraocular contact lenses" or "intraocular lens implantation. ". The field of refractive surgery includes lens-based procedures using products such as ICL and laser-based procedures such as LASIK surgery. Successful refractive surgery can correct common vision disorders such as nearsightedness, farsightedness and astigmatism. STAAR Surgical was originally incorporated in California in 1982 and re-merged in Delaware in 1986.
Company Financials
EPS
STAA has released its 2024 Q4 earnings. EPS was reported at -0.69, versus the expected 0.00, missing expectations. The chart below visualizes how STAA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
STAA has released its 2024 Q4 earnings report, with revenue of 48.95M, reflecting a YoY change of -35.82%, and net profit of -34.23M, showing a YoY change of -541.31%. The Sankey diagram below clearly presents STAA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available